USPRegulatory IntelligenceStandardHIGH INSPECTION RISK
USP <797>

Pharmaceutical Compounding — Sterile Preparations

The compendial standard for compounding sterile preparations: facility design and air quality, personnel garbing and competency including gloved-fingertip and media-fill testing, environmental monitoring, sterilisation and depyrogenation, and beyond-use dating by preparation category. The revised chapter became official 1 November 2023.

LAST REVISED
November 2023
PRODUCT AREAS
Sterile
SCOPE & APPLICABILITY

Any setting preparing compounded sterile preparations, including hospital pharmacies, infusion providers and 503B outsourcing facilities.

KEY REQUIREMENTS
  • 01Designated person accountable for the sterile compounding programme
  • 02Personnel qualification: garbing competency, gloved-fingertip testing and media fills at defined intervals
  • 03Certified engineering controls with ISO-classified air appropriate to the operation
  • 04Viable and non-viable environmental monitoring with defined action levels and investigation
  • 05BUDs assigned per CSP category, with the required testing in place
  • 06Master formulation and compounding records for each preparation
IMPLEMENTATION TIPS
Decide the CSP category from the sterility-assurance system you can actually sustain, then let the BUD follow — never the reverse
Media fills are the qualification most often deferred and the one an inspector asks for first
Where the site is a 503B facility, run <797> and 21 CFR 211 as one programme rather than two parallel ones
REVISION NOTES

Revised chapter official 1 November 2023: CSP Categories 1–3, revised BUD framework, strengthened personnel qualification.

USP <797>: frequently asked questions

Quick answers to common questions about USP <797>.

What is USP <797>?

USP <797> — Pharmaceutical Compounding — Sterile Preparations — is a standard issued by the United States Pharmacopeia (United States / International). The compendial standard for compounding sterile preparations: facility design and air quality, personnel garbing and competency including gloved-fingertip and media-fill testing, environmental monitoring, sterilisation and depyrogenation, and beyond-use dating by preparation category. The revised chapter became official 1 November 2023.

Who does USP <797> apply to?

Any setting preparing compounded sterile preparations, including hospital pharmacies, infusion providers and 503B outsourcing facilities.

What are the key requirements of USP <797>?

USP <797> requires, among other things: Designated person accountable for the sterile compounding programme; Personnel qualification: garbing competency, gloved-fingertip testing and media fills at defined intervals; Certified engineering controls with ISO-classified air appropriate to the operation; Viable and non-viable environmental monitoring with defined action levels and investigation.

When was USP <797> last updated?

The current version of USP <797> dates from November 2023. Revised chapter official 1 November 2023: CSP Categories 1–3, revised BUD framework, strengthened personnel qualification.

RELATED STANDARDS
RELATED FDA RECALLS
where Environmental Monitoring control fails
See all Environmental Monitoring recalls →

Live openFDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.

THIS STANDARD IN PRACTICE

Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.

Weekly Briefing

Track the standards that move

When USP <797> — or any GxP requirement — is revised, recalled against, or clarified by new guidance, the Weekly GxP Briefing surfaces it. Free, one email a week.

Read a past issue →